Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Nonfunctioning Pituitary Adenoma

Abstract

Objectives Hypofractionated stereotactic radiotherapy (HSRT) in two to five fractions may offer patients with large nonfunctioning pituitary adenomas (NFPAs) with chiasm involvement a safe and effective treatment over a single week. However, little has been reported regarding this novel approach.

Design We compared the feasibility, outcomes, and toxicity of single-fraction stereotactic radiosurgery and HSRT.

Setting This study was conducted at a tertiary academic referral center.

Participants After approval by the institutional review board, we performed a retrospective cohort study of patients treated at our institution with stereotactic radiosurgery (SRS) and HSRT for NFPA. Selection for SRS or HSRT was based on clinicopathologic factors including tumor size and cavernous sinus invasion at the discretion of the treating physician.

Main Outcome Measures Local control, endocrinopathy, and radiation-associated toxicity were evaluated by binary logistic regression and Cox's proportional hazards regression.

Results A total of 45 patients with mean follow-up of 5 years were enrolled including 26 patients treated by HSRT with mean follow-up of 3 years and 19 patients treated by SRS with median follow-up of 6 years. Clinicopathologic characteristics were balanced between cohorts. Local failure at last follow-up was 5% in the SRS cohort and 8% in the HSRT cohort, and rates of post-SRS endocrinopathy were similar between each cohort. Late complications including radionecrosis, visual deficit, and secondary malignancy were minimal in either cohort.

Conclusions HSRT is an appropriate treatment strategy for patients with NFPAs, particularly for optic pathway preservation in the setting of large tumors with chiasm involvement. Further studies are needed to optimize fractionated approaches and patient selection.

Keywords

Hypofractionated Stereotactic Radiotherapy - stereotactic radiosurgery - non-functioning pituitary adenoma - fractionation - toxicity

^* These authors contributed equally to this work.

Publikationsverlauf

Eingereicht: 04. Oktober 2019

Angenommen: 14. März 2020

Artikel online veröffentlicht:
05. Mai 2020

• References

• 1 Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72 (03) 377-382
• 2 Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010; 95 (09) 4268-4275
• 3 Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96 (07) 1992-2003
• 4 Tishler RB, Loeffler JS, Lunsford LD. et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993; 27 (02) 215-221
• 5 Sheehan JP, Starke RM, Mathieu D. et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg 2013; 119 (02) 446-456
• 6 Starke RM, Williams BJ, Jane Jr. JA, Sheehan JP. Gamma Knife surgery for patients with nonfunctioning pituitary macroadenomas: predictors of tumor control, neurological deficits, and hypopituitarism. J Neurosurg 2012; 117 (01) 129-135
• 7 Yeung JT, Karim SA, Chang SD. Multi-session radiosurgery of benign intracranial tumors. Neurosurg Clin N Am 2013; 24 (04) 543-551
• 8 Khattab MH, Sherry AD, Whitaker R. et al. A retrospective cohort study of longitudinal audiologic assessment in single and fractionated stereotactic radiosurgery for vestibular schwannoma. Neurosurgery 2019; 85 (06) E1078-E1083
• 9 Soliman H, Myrehaug S, Tseng CL. et al. Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases. Neurosurgery 2019; 85 (05) E860-E869
• 10 Fowler JF. 21 years of biologically effective dose. Br J Radiol 2010; 83 (991) 554-568
• 11 Niranjan A, Flickinger JC. Radiobiology, principle and technique of radiosurgery. Prog Neurol Surg 2008; 21: 32-42
• 12 Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 1993; 25 (02) 381-385
• 13 Kondziolka D, Shin SM, Brunswick A, Kim I, Silverman JS. The biology of radiosurgery and its clinical applications for brain tumors. Neuro-oncol 2015; 17 (01) 29-44
• 14 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
• 15 Cahan WG, Woodard HQ. et al. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1948; 1 (01) 3-29
• 16 van den Bergh ACM, van den Berg G, Schoorl MA. et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007; 67 (03) 863-869
• 17 Erridge SC, Conkey DS, Stockton D. et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 2009; 93 (03) 597-601
• 18 Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007; 84 (01) 79-84
• 19 Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 2011; 114 (02) 303-309
• 20 Pollock BE, Cochran J, Natt N. et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008; 70 (05) 1325-1329
• 21 Voges J, Kocher M, Runge M. et al. Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer 2006; 107 (06) 1355-1364
• 22 Liao HI, Wang CC, Wei KC. et al. Fractionated stereotactic radiosurgery using the Novalis system for the management of pituitary adenomas close to the optic apparatus. J Clin Neurosci 2014; 21 (01) 111-115
• 23 Iwata H, Sato K, Tatewaki K. et al. Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-oncol 2011; 13 (08) 916-922
• 24 Killory BD, Kresl JJ, Wait SD, Ponce FA, Porter R, White WL. Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurgery 2009; 64 (2, Suppl): A19-A25
• 25 Adler Jr JR, Gibbs IC, Puataweepong P, Chang SD. Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery 2006; 59 (02) 244-254
• 26 Pham CJ, Chang SD, Gibbs IC, Jones P, Heilbrun MP, Adler Jr. JR. Preliminary visual field preservation after staged CyberKnife radiosurgery for perioptic lesions. Neurosurgery 2004; 54 (04) 799-810
• 27 Kirkpatrick JP, Marks LB, Mayo CS, Lawrence YR, Bhandare N, Ryu S. Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. J Radiosurg SBRT 2011; 1 (02) 95-107
• 28 Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62 (740) 679-694
• 29 Cleary RK, Meshman J, Dewan M. et al. Postoperative fractionated stereotactic radiosurgery to the tumor bed for surgically resected brain metastases. Cureus 2017; 9 (05) e1279
• 30 Han J, Girvigian MR, Chen JCT. et al. A comparative study of stereotactic radiosurgery, hypofractionated, and fractionated stereotactic radiotherapy in the treatment of skull base meningioma. Am J Clin Oncol 2014; 37 (03) 255-260
• 31 Milano MT, Grimm J, Soltys SG. et al. Single- and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways. Int J Radiat Oncol Biol Phys 2018
• 32 Sahgal A. Technological advances in brain and spine radiosurgery. Technol Cancer Res Treat 2012; 11 (01) 1-2
• 33 Ahmad SS, Duke S, Jena R, Williams MV, Burnet NG. Advances in radiotherapy. BMJ 2012; 345: e7765
• 34 Minniti G, Osti MF, Niyazi M. Target delineation and optimal radiosurgical dose for pituitary tumors. Radiat Oncol 2016; 11 (01) 135
• 35 Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD. The radiosurgery fractionation quandary: single fraction or hypofractionation?. Neuro-oncol 2017; 19 (02, Suppl 2): ii38-ii49